RVT-1401

Phase 2Small molecule

IImmunovant Sciences GmbH

RVT-1401 is one of 53 small molecule programs targeting Myasthenia Gravis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Myasthenia GravisActive, not recruiting

Warm Autoimmune Hemolytic AnemiaActive, not recruiting

Myasthenia GravisPhase 2

Active, not recruiting

Warm Autoimmune Hemolytic AnemiaPhase 2

Active, not recruiting

Competition

Competitive Landscape

102 competitors in Myasthenia Gravis

#DrugCompanyPhaseTrials

Rituxan

Roche

Phase 3

7 2

Ultomiris

AstraZeneca

Phase 3

5 3

Vyvgart

Argenx

Phase 3

17 4

Soliris

AstraZeneca

Phase 3

4 5

Cellcept

Roche

Phase 3

4 6

Zilbrysq

UCB

Phase 3

4 7

Fabhalta

Johnson & Johnson

Phase 3

3 8

ENSPRYNG

Roche

Phase 3

1 9

Arava

Sanofi

Phase 3

1 10

Rhapsido

Novartis

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Treatment2 trials

ASCEND GO-2: Study of RVT-1401 for the Treatment of Participants With Active, Moderate to Severe Graves' Ophthalmopathy ( GO )

Terminated·IImmunovant Sciences GmbH·Phase 2·NCT03938545·65 enrolled

Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves' Ophthalmopathy (GO)

Completed·IImmunovant Sciences GmbH·Phase 2·NCT03922321·7 enrolled

Myasthenia Gravis1 trial

A Study of RVT-1401 in Myasthenia Gravis (MG) Patients

Completed·IImmunovant Sciences GmbH·Phase 2·NCT03863080·17 enrolled

Warm Autoimmune Hemolytic Anemia1 trial

To Assess the Efficacy and Safety of RVT-1401 in the Treatment of Warm Autoimmune Hemolytic Anemia (ASCEND-WAIHA).

Terminated·IImmunovant Sciences GmbH·Phase 2·NCT04253236·5 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for RVT-1401. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RVT-1401 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RVT-1401. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Immunovant Sciences GmbH company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: IImmunovant Sciences GmbH

RVT-1401

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Treatment2 trials

Myasthenia Gravis1 trial

Warm Autoimmune Hemolytic Anemia1 trial

References

Drug Info

Quick Facts

Related News